NFKB1 and triple-A syndrome: Overall, our data proved that the new STAT3 inhibitor, BP-1-102, significantly inhibited AngII-induced AAA progression through reducing vascular inflammation-related JAK2/STAT3 and NF-κB signaling pathways and maintaining autophagy.